Compare BHST & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHST | FBIO |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.2M | 113.9M |
| IPO Year | N/A | N/A |
| Metric | BHST | FBIO |
|---|---|---|
| Price | $5.77 | $3.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $14.00 | ★ $16.50 |
| AVG Volume (30 Days) | 37.2K | ★ 1.2M |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $32,720,000.00 | ★ $62,303,000.00 |
| Revenue This Year | $116.40 | $29.71 |
| Revenue Next Year | $55.91 | $49.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 45.88 | N/A |
| 52 Week Low | $4.72 | $1.33 |
| 52 Week High | $12.80 | $4.53 |
| Indicator | BHST | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 55.59 | 47.17 |
| Support Level | $4.80 | $3.33 |
| Resistance Level | $5.45 | $3.79 |
| Average True Range (ATR) | 0.41 | 0.33 |
| MACD | 0.11 | -0.11 |
| Stochastic Oscillator | 71.86 | 18.36 |
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.